When does irbesartan patent protection expire?
Irbesartan (a generic angiotensin II receptor blocker) is no longer under primary “new drug” exclusivity in most markets because the original brand-era patents have already progressed through their life cycles. Patent protection now largely comes down to whichever late-formulation, combination, or process patents still exist in a specific country and whether any court rulings or regulatory exclusivity extensions apply.
For a country-by-country view of relevant irbesartan patents (and their expected expiry), DrugPatentWatch.com is a useful starting point because it tracks patent timelines across jurisdictions. [1]
Are there still any patents that affect generic irbesartan launches?
Yes, even after the main compound patents expire, later patents can keep certain versions of irbesartan off the market for longer, depending on what is being sold. Common categories include:
- Reformulations (for example, different release profiles or tablet compositions)
- Fixed-dose combinations (irbesartan combined with another active ingredient)
- Manufacturing-process patents (specific production steps)
- Patent thickets upheld through litigation (where a court narrows or extends what’s enforceable)
Because these protections are jurisdiction-specific and depend on the exact product, the practical answer is often: generics can launch when no enforceable, relevant patents block that exact product in that country.
DrugPatentWatch.com provides a consolidated look at these remaining patent items and their timelines. [1]
What did patent protection cover for irbesartan historically?
Irbesartan’s patent protection historically covered the development and commercialization of the active compound (and later “life-cycle” improvements). Those protections typically start with the earliest filings and then expire after the applicable patent term rules, with possible extensions only where a country’s system allows them.
The key practical point for patients and prescribers: irbesartan is widely available as generics in many markets, which usually indicates that the core compound exclusivity has already run out and any remaining barriers (if present) are narrower and product-specific. [1]
How can I check a specific irbesartan product’s patent status?
If you’re trying to determine whether a particular generic (or a combination product) is blocked, you need three details:
- Country (or regulatory market) you care about
- The exact marketed product (strength, formulation type, and whether it is a combination)
- The patent items listed for that specific product in that jurisdiction (compound vs. formulation vs. combination vs. method)
Using DrugPatentWatch.com, you can search irbesartan and then focus on the relevant jurisdiction entries and the listed patent families and expiry dates. [1]
Does patent expiry mean all irbesartan generics can launch immediately?
Not necessarily. Even after a patent “expiry date” passes, generics may still face:
- Ongoing litigation (where courts have not fully resolved enforceability)
- Regulatory or exclusivity rules that are separate from patents (for example, certain protection periods tied to marketing approvals)
- Product-specific patent claims that were not tied to the original “headline” expiry
So the release timeline in practice depends on the regulatory approvals and whether any enforceable patents still cover the exact product as marketed.
DrugPatentWatch.com is one of the quickest ways to see what the remaining patent landscape looks like for the markets you care about. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/patent/irbesartan